TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$1.79 USD
+0.07 (4.07%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.78 -0.01 (-0.56%) 5:38 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TCRX 1.79 +0.07(4.07%)
Will TCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Beats Revenue Estimates
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates
TCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates
Other News for TCRX
Is TCRX set to rally? Stochastic Buy Signal shows up after soaring 7.5%
Is TCRX setting up for a drop? Reversal New Lows Setup shows up after plummeting 6.98%
H.C. Wainwright Sticks to Their Buy Rating for TScan Therapeutics (TCRX)
Is TCRX set to rally? Hammer Candlestick shows up after gaining 1.78%
Bollinger Band Squeeze appears for TCRX after 3.98% move